Hungary's medicines authority. The work was done by OGYÉI until 2023, then by the National Centre for Public Health and Pharmacy, and from 1 November 2026 by a new National Institute of Pharmacy. New cancer medicines are authorised for the whole EU through the European Medicines Agency.
The National Centre for Public Health and Pharmacy (NNGYK) states that it was formed on 1 August 2023 when the National Institute of Pharmacy and Nutrition (Országos Gyógyszerészeti és Élelmezés-egészségügyi Intézet, OGYÉI) merged into the National Public Health Centre, and that as an authority it was responsible for medicines supervision and the pharmaceutical market. Its notice of 3 November 2026 says that under Government Decree 324/2026 (X. 29.) the pharmaceutical tasks were split off on 1 November 2026 into the Országos Gyógyszerészeti Intézet (OGYI), a separate central office that is the legal successor for those tasks.
New active substances for cancer go through the EU centralised procedure, so they are authorised in Hungary at the same time as elsewhere in the EU. The OECD and European Commission's 2025 profile notes that since August 2023 the pharmacy authority has also carried out the mandatory health technology assessment of new medicines. The authority's medicines database and adverse reaction reporting site at ogyei.gov.hu were suspended from 22 to 26 October 2026 after a national cyber security alert, according to NNGYK.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/